geh200521
BiologicalexperimentalImaging agent
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 2, 2024 (NCT06398730)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-cell surface glycoprotein CD8 alpha chainBINDING AGENT
CD8A binding agent
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06398730 | Phase 1 | Jul 2, 2024 | Fortrea, General Electric, PPD |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fortrea | For profit | 1 | 0 | 1 | 2024 |
| General Electric | For profit | 1 | 1 | 1 | 2024 |
| PPD | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1